Compare
Indaptus Therapeutics, Inc. vs Soligenix, Inc. vs ProMIS Neurosciences Inc. vs Kala Bio, Inc.
| Latest fiscal year | Indaptus Therapeutics, Inc. INDP | Soligenix, Inc. SNGX | ProMIS Neurosciences Inc. PMN | Kala Bio, Inc. KALA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$20.85M | -$11.08M | -$39.72M | -$26.98M |
| EPS (Diluted) | -$21.58 | -$2.14 | -$22.61 | -$3.31 |
| Operating cash flow | -$14.82M | -$10.27M | -$28.12M | -$31.99M |
| Free cash flow | n/a | -$10.27M | n/a | n/a |
| Cash & equivalents | $8.51M | n/a | $6.12M | $7.56M |
| Total assets | $9.31M | $9.24M | $9.18M | $9.49M |
| Total liabilities | n/a | $3.94M | $10.44M | $2.49M |
| Shareholders' equity | $3.15M | $5.29M | -$1.26M | $7.00M |
| Return on year-end equity | -661.5% | -209.4% | n/a | -385.6% |
| Shares outstanding | 2.17M | 10.09M | 2.15M | 27.85M |
Revenue, most recent five fiscal years
| Fiscal year | Indaptus Therapeutics, Inc. | Soligenix, Inc. | ProMIS Neurosciences Inc. | Kala Bio, Inc. |
|---|---|---|---|---|
| Latest | n/a | $119.4K Ended 2024-12-31 | n/a | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $839.4K Ended 2023-12-31 | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $948.9K Ended 2022-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $824.3K Ended 2021-12-31 | n/a | $3.89M Ended 2022-12-31 |
| 4 years earlier | n/a | $2.36M Ended 2020-12-31 | n/a | $11.24M Ended 2021-12-31 |